Safety Profiles of Bispecific Antibodies for RRMM

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Issam S. Hamadeh, PharmD, BCPS, BCOP

Key Takeaways

Bispecific therapies for RRMM often lead to CRS and ICANS, necessitating careful monitoring and management to mitigate these immune-related adverse events.
Increased infection risks are a significant concern with bispecific therapies, requiring proactive measures to prevent and manage infections in patients.
Talquetamab exhibits unique toxicities, including nail-related issues like paronychia, skin-related toxicities such as rash, and oral-related toxicities like dysgeusia.
Effective management of talquetamab's unique toxicities is crucial to ensure patient adherence and optimize therapeutic outcomes.

Panelists discuss how bispecific antibody therapies in relapsed/refractory multiple myeloma commonly present with cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and increased infection risks, while talquetamab specifically exhibits distinctive adverse events including nail changes, skin reactions, and oral toxicities.

EP: 1.Current Landscape of Bispecific Therapies for RRMM

EP: 2.Operationalizing Bispecific Therapy and the Impact of CAR-T Advancements on Sequencing

EP: 3.Best Practices for Standardizing Step-Up Dosing

EP: 4.Dosing Frequency and Formulary Decisions for Bispecific Antibodies

EP: 5.Resources and Education for Operationalizing Bispecifics

Now Viewing

EP: 6.Safety Profiles of Bispecific Antibodies for RRMM

Video content above is prompted by the following

Provide a brief overview of typical toxicities seen with bispecific therapies for RRMM, namely CRS/ICANS and infection risks.
Describe the unique toxicities seen with talquetamab, namely nail-related, skin-related, and oral-related toxicities.